Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Declines By 27.3%

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant decline in short interest in January. As of January 15th, there was short interest totaling 4,183,761 shares, a decline of 27.3% from the December 31st total of 5,752,164 shares. Based on an average daily trading volume, of 723,298 shares, the short-interest ratio is currently 5.8 days. Currently, 7.7% of the shares of the company are short sold. Currently, 7.7% of the shares of the company are short sold. Based on an average daily trading volume, of 723,298 shares, the short-interest ratio is currently 5.8 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS Group AG raised its holdings in shares of Astria Therapeutics by 313.5% in the 4th quarter. UBS Group AG now owns 2,399,171 shares of the biotechnology company’s stock valued at $31,405,000 after purchasing an additional 1,819,020 shares in the last quarter. Vestal Point Capital LP increased its holdings in Astria Therapeutics by 9.6% in the third quarter. Vestal Point Capital LP now owns 4,956,000 shares of the biotechnology company’s stock valued at $36,080,000 after buying an additional 434,000 shares during the last quarter. Millennium Management LLC increased its holdings in Astria Therapeutics by 2.2% in the third quarter. Millennium Management LLC now owns 3,034,527 shares of the biotechnology company’s stock valued at $22,091,000 after buying an additional 64,800 shares during the last quarter. Brevan Howard Capital Management LP acquired a new stake in Astria Therapeutics in the third quarter valued at $98,000. Finally, Raymond James Financial Inc. lifted its holdings in Astria Therapeutics by 6.0% during the 3rd quarter. Raymond James Financial Inc. now owns 96,020 shares of the biotechnology company’s stock worth $699,000 after buying an additional 5,437 shares during the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Stock Up 0.6%

Shares of ATXS opened at $12.58 on Friday. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $13.29. The company has a market capitalization of $718.13 million, a PE ratio of -5.88 and a beta of 0.01. The stock has a fifty day simple moving average of $12.77 and a two-hundred day simple moving average of $10.09.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The firm had revenue of $0.71 million for the quarter, compared to analyst estimates of $10.67 million. As a group, equities analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. JMP Securities restated a “market perform” rating on shares of Astria Therapeutics in a research report on Wednesday, October 15th. Citizens Jmp lowered shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 15th. Lifesci Capital cut shares of Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Cantor Fitzgerald downgraded shares of Astria Therapeutics from an “overweight” rating to a “neutral” rating in a report on Wednesday, November 12th. Finally, Oppenheimer cut shares of Astria Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $24.50.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.